Serum amyloid A and misfolded transthyretin may be the two predictable biomarkers to relapsed/ refractory diffuse large B cell lymphoma

Saved in:
Bibliographic Details
Published inAsian journal of surgery Vol. 45; no. 6; pp. 1301 - 1302
Main Authors Liu, Hu, Liu, Shu-Ying, Zhang, Qiao-Hua, Hou, Shu-Ling
Format Journal Article
LanguageEnglish
Published China Elsevier Taiwan LLC 01.06.2022
Elsevier
Subjects
Antineoplastic Combined Chemotherapy Protocols
Biomarkers
Humans
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphoma, Large B-Cell, Diffuse - therapy
Lymphoma, Non-Hodgkin - drug therapy
Prealbumin - therapeutic use
Recurrence
Serum Amyloid A Protein
Treatment Outcome
Online AccessGet full text

Cover

More Information
ISSN:1015-9584
0219-3108
DOI:10.1016/j.asjsur.2022.01.131